High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: Promising candidates for vascular targeting applications

Endocrine-Related Cancer

Volumn 16, Issue 2, 2009, Pages 623-633

  Fleischmann, Achim ^a   Waser, Beatrice ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN[6-13][6 DEXTRO PENTAFLUOROPHENYLALANINE 11 DEXTRO ALANINE] METHYL ESTER; GASTRIN RELEASING PEPTIDE RECEPTOR; IODINE 125; BOMBESIN; BOMBESIN RECEPTOR; RADIOACTIVE IODINE;

ADENOCARCINOMA; ARTICLE; AUTORADIOGRAPHY; CANCER LOCALIZATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; PREVALENCE; PROSTATE CANCER; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; URINARY TRACT CANCER; FEMALE; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; VASCULARIZATION;

AUTORADIOGRAPHY; BOMBESIN; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; PROGNOSIS; RECEPTORS, BOMBESIN; UROLOGIC NEOPLASMS;

EID: 67650433928     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0316     Document Type: Article

References (52)

1. Auguste P, Lemiere S, Larrieu-Lahargue F & Bikfalvi A 2005 Molecular mechanisms of tumor vascularization. Critical Reviews in Oncology/ Hematology 54 53-61.
2. Bajo AM, Schally AV, Groot K & Szepeshazi K 2004 Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. British Journal of Cancer 90 245-252.
3. Bjenning C, Farrell AP & Holmgren S 1991 Bombesin-like immunoreactivity in skates and the in vitro effect of bombesin on coronary vessels from the longnose skate, Raja rhina. Regulatory Peptides 35 207-219.
4. Bologna M, Festuccia C, Muzi P, Biordi L & Ciomei M 1989 Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63 1714-1720.
5. Brack SS, Dinkelborg LM & Neri D 2004 Molecular targeting of angiogenesis for imaging and therapy. European Journal of Nuclear Medicine and Molecular Imaging 31 1327-1341.
6. Bunnett N 1994 Gastrin-releasing peptide. In Gut Peptides: Biochemistry and Physiology, pp 423-445. Eds JH Walsh & GJ Dockray. New York: Raven Press, Ltd.
7. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V & Reubi JC 2008 Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Journal of Nuclear Medicine 49 318-326.
8. Clive S, Jodrell D & Webb D 2001 Gastrin-releasing peptide is a potent vasodilator in humans. Clinical Pharmacology and Therapeutics 69 252-259.
9. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A & Minna JD 1985 Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316 823-826.
10. Dome B, Hendrix MJ, Paku S, Tovari J & Timar J 2007 Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. American Journal of Pathology 170 1-15.
11. Engel JB, Schally AV, Halmos G, Baker B, Nagy A & Keller G 2005 Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocrine-Related Cancer 12 999-1009.
12. Fleischmann A, Laderach U, Friess H, Buechler MW & Reubi JC 2000 Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Laboratory Investigation 80 1807-1817.
13. Fleischmann A, Waser B, Gebbers JO & Reubi JC 2005 Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. Journal of Clinical Endocrinology and Metabolism 90 4722-4729.
14. Fleischmann A, Waser B & Reubi JC 2007 Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cellular Oncology 29 421-433.
15. Gugger M & Reubi JC 1999 Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. American Journal of Pathology 155 2067-2076.
16. Heuser M, Schlott T, Schally AV, Kahler E, Schliephake R, Laabs SO & Hemmerlein B 2005 Expression of gastrin releasing peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. Journal of Urology 173 2154-2159.
17. Jain RK 2003 Molecular regulation of vessel maturation. Nature Medicine 9 685-693.
18. Jensen JA, Carroll RE & Benya RV 2001 The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22 689-699.
19. Jensen RT, Battey JF, Spindel ER & Benya RV 2008 International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological Reviews 60 1-42.
20. Kanashiro CA, Schally AV, Cai RZ & Halmos G 2005 Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anticancer Research 16 159-165.
21. Kanashiro CA, Schally AV, Zarandi M, Hammann BD & Varga JL 2007 Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. International Journal of Oncology 30 1019-1028.
22. Kang J, Ishola TA, Baregamian N, Mourot JM, Rychahou PG, Evers BM & Chung DH 2007 Bombesin induces angiogenesis and neuroblastoma growth. Cancer Letters 253 273-281.
23. Kim JS, McKinnis VS & White SR 1997 Migration of guinea pig airway epithelial cells in response to bombesin analogues. American Journal of Respiratory Cell and Molecular Biology 16 259-266.
24. Korner M & Reubi JC 2007 NPY receptors in human cancer: a review of current knowledge. Peptides 28 419-425.
25. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T et al. 2006 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. Journal of Nuclear Medicine 47 1144-1152.
26. Levine L, Licci JA III, Townsend CM Jr & Hellmich MR 2003a Expression of gastrin-releasing peptide receptors in endometrial cancer. Journal of the American College of Surgeons 196 898-904.
27. Levine L, Lucci JA III, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr & Hellmich MR 2003b Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Research 63 3495-3502.
28. Luu TN, Chester AH, O'Neil GS, Tadjkarimi S, Pepper JR & Yacoub MH 1993 Different responses of the human gastroepiploic and internal mammary arteries to vasoactive peptides. American Journal of Physiology 264 H583-H587.
29. Markwalder R & Reubi JC 1999 Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research 59 1152-1159.
30. Martinez A 2006 A new family of angiogenic factors. Cancer Letters 236 157-163.
31. Martinez A, Zudaire E, Julian M, Moody TW & Cuttitta F 2005 Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene 24 4106-4113.
32. Mitra AP, Datar RH & Cote RJ 2006 Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. Journal of Clinical Oncology 24 5552-5564.
33. Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, Gonzales N, Fuselier JA, Coy DH & Jensen RT 2006 In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. Journal of Pharmacology and Experimental Therapeutics 318 1265-1272.
34. Narazaki M & Tosato G 2005 Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studies. Journal of the National Cancer Institute 97 705-707.
35. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC & Maina T 2005 Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. Journal of Medicinal Chemistry 48 100-110.
36. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE & Schnitzer JE 2004 Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429 629-635.
37. Otrock ZK, Mahfouz RA, Makarem JA & Shamseddine AI 2007 Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells, Molecules & Diseases 39 212-220.
38. Patel O, Shulkes A & Baldwin GS 2006 Gastrin-releasing peptide and cancer. Biochimica et Biophysica Acta 1766 23-41.
39. Rettenbacher M & Reubi JC 2001 Localization and characterization of neuropeptide receptors in human colon. Naunyn-Schmiedeberg's Archives of Pharmacology 364 291-304.
40. Reubi JC & Waser B 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 30 781-793.
41. Reubi JC, Schaer JC, Laissue JA & Waser B 1996 Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45 39-41.
42. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC & Gugger M 2002 Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), β-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clinical Cancer Research 8 1139-1146.
43. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ & Zarandi M 2005 Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 64 303-315.
44. Thorpe PE, Chaplin DJ & Blakey DC 2003 The first international conference on vascular targeting: meeting overview. Cancer Research 63 1144-1147.
45. Vigna SR, Mantyh CR, Giraud AS, Soll AH, Walsh JH & Mantyh PW 1987 Localization of specific binding sites for bombesin in the canine gastrointestinal tract. Gastroenterology 93 1287-1295.
46. de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP & de Jong M 2007 Novel (111)In-labelled bombesin analogues for molecular imaging of prostate tumours. European Journal of Nuclear Medicine and Molecular Imaging 34 1228-1238.
47. de Visser M, Verwijnen SM & de Jong M 2008 Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biotherapy & Radiopharmaceuticals 23 137-157.
48. Waser B, Eltschinger V, Linder K, Nunn A & Reubi JC 2007 Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer (177)Lu-AMBA. European Journal of Nuclear Medicine and Molecular Imaging 34 95-100.
49. Yano T, Pinski J, Groot K & Schally AV 1992 Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Research 52 4545-4547.
50. Yule KA & White SR 1999 Migration of 3T3 and lung fibroblasts in response to calcitonin gene-related peptide and bombesin. Experimental Lung Research 25 261-273.
51. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC & Maecke HR 2004 Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Research 64 6707-6715.
52. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC & Maecke HR 2007 DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. European Journal of Nuclear Medicine and Molecular Imaging 34 1198-1208.